

Management of cardiovascular disease

Diabetes and coronary revascularization

Recommendation	Class	Level
Treatment decisions regarding revascularization in patients with diabetes should favour coronary artery bypass surgery over percutaneous intervention.	IIa	A
Glycoprotein IIb/IIIa inhibitors are indicated in elective PCI in a diabetic patient.	I	B
When PCI with stent implantation is performed in a diabetic patient, drug-eluting stents (DES) should be used.	IIa	B
Mechanical reperfusion by means of primary PCI is the revascularization mode of choice in a diabetic patient with acute MI.	I	A

Management of diabetes and glucose control before, during and after PCI and CABG

Diabetes and coronary revascularization

By pass surgery versus PCI

Adjunctive therapy

Revascularization in acute coronary syndromes

Glucose control

Unresolved issues


Management of diabetes and glucose control before, during and after PCI and CABG

Diabetes and coronary revascularization

Diabetes and coronary revascularization

Registry study - Duke University data base

n= 3 220 (diabetes 24%) with 2-3 VD. Interventions: 1984 - 1990



Patients with Diabetes

CABG	626	506	358
PTCA	144	113	79


Patients without Diabetes

CABG	1890	1635	1287
PTCA	560	444	323

(Barnes et al Circulation 1997;96:2551)

Diabetes and coronary revascularization

The BARI randomized trial comparing CABG and PCI
 Patients n = 1829; Diabetes n=353 (19%)



No. of Patients					
ND CABG	734	698	669	613	473
ND PTCA	742	703	675	621	477
D CABG	180	161	143	124	80
D PTCA	173	139	115	93	63

(The BARI investigators JACC 2007; 49:1600)

Diabetes and coronary revascularization

Coronary interventions in patients with vs. without diabetes

- Coronary Bypass Surgery
 - Higher mortality
 - More frequent complications
 - infections, delayed wound healing...
- Percutaneous coronary angioplasty
 - Higher mortality
 - High restenosis rate
 - Increased rate of stent thrombosis
 - More frequent repeat revascularizations

Management of diabetes and glucose control before, during and after PCI and CABG

Diabetes and coronary revascularization

By pass surgery versus PCI

By pass surgery by diabetic state

North American retrospective cohort study
30 day mortality and morbidity in CABG


No diabetes n = 105 123 Diabetes n = 41663 (28%)

Variable	Diabetes		Adjusted OR
	No	Yes	
Mortality	2.7	3.7	1.23 (1.15-1.32)
Morbidity	9.1	13.9	1.38 (1.33-1.44)
MI, Stroke, Organ failure			
Infection	5.2	7.9	1.36 (1.30-1.40)
Pneumonia, Urinary tract, Sternal			
Septicemia	0.9	1.4	
Mortality or morbidity	10.4	15.5	

(Carson et al JACC 2002; 40:202)

PCI by diabetic state


Subgroup analysis – pooled data (n= 10 777)
Endpoint: death, MI or repeat revascularisation



(After Mak & Faxon Europ Heart J 2003; 24:1087)

By pass surgery versus PCI


Subgroup analysis - registry studies comparing CABG and PCI
Survival in patients with diabetes (n= 8 817)



(After Mak & Faxon Europ Heart J 2003; 24:1087)

By pass surgery versus PCI

Subgroup analysis - RCT comparing CABG and PCI
Survival in patients with diabetes (n= 627)




(After Mak & Faxon Europ Heart J 2003; 24:1087)

By pass surgery versus PCI

The BARI randomized trial comparing CABG and PCI
Patients with diabetes (n=353)

Five year mortality by type of intervention




(The Bari Investigators Circulation 1997; 96:1761)

By pass surgery versus PCI

Stenting vs. CABG in multivessel disease
Subgroup analysis from ARTS

Multivessel disease n = 1 205 Diabetes n = 208 (17%)

Three year survival free from stroke, MI and revascularization




(Serruys et al Circulation 2004; 109:1114)

By pass surgery versus PCI

CABG and PCI in the era of drug eluting stents (Cypher)
 Patients with diabetes (n = 518)
 Matched pairs CABG (n = 86) PCI (n = 86)


Survival free from

Angina



MIDCAB	83	81	79	74	67	58	53	50	46
CYPHER	83	79	75	71	65	54	40	25	14

New interventions




MIDCAB	83	81	80	75	69	60	56	53	49
CYPHER	83	82	78	76	74	63	50	30	19

(Ben-Gal et al. Ann Thorac Surg 2006; 82:2006)

Bare metal vs. drug eluting stents

RCT in patients with diabetes

Sirolimus (n = 80; 111 lesions) Bare metal (n = 80; 110 lesions)
End-point: in segment late lumen loss by QCA after 9 months




(Sabaté et al. Circulation 2005; 112:2175)

L Rydén MD, FRCP, FESC

By pass surgery versus PCI

Drug eluting stents (sirolimus)

Four years survival in patients with diabetes (n = 428)



HR 2.90 (95% CI 1.38-6.10)
p=0.008

Bare Metal Stents
96%

Drug eluting stents
SIROLIMUS
88%

No. at Risk

Bare-metal stent	233	230	227	221	197
Sirolimus stent	195	188	185	175	158

(Spaulding et al New Engl J Med 2007; 356:989)

Management of diabetes and glucose control before, during and after PCI and CABG

Diabetes and coronary revascularization

Recommendation	Class	Level
Treatment decisions regarding revascularization in patients with diabetes should favour coronary artery bypass surgery over percutaneous intervention.	IIa	A
Whenever possible, patients with diabetes should be offered at least one and often multiple arterial grafts	I	C

For more information
www.escardio.org

Management of diabetes and glucose control before, during and after PCI and CABG


Diabetes and coronary revascularization

By pass surgery versus PCI

Adjunctive therapy

Adjunctive therapy - Abciximab

Subgroup analysis of three RCT (EPIC, EPILOG, EPISTENT)
Pooled patients with (n= 1 462) vs. without diabetes (n= 5 072)



(Bhatt et al. JACC 2000; 35:922)

Management of diabetes and glucose control before, during and after PCI and CABG

Diabetes and coronary revascularization

Glycoprotein IIb/IIIa inhibitors are indicated in elective PCI in a diabetic patient.

I

B

Management of diabetes and glucose control before, during and after PCI and CABG

Diabetes and coronary revascularization


By pass surgery versus PCI

Adjunctive therapy

Revascularization in acute coronary syndromes

Revascularization in acute coronary syndromes


Early revascularization in ACS comparing patients with (n=155) and without diabetes (n=1 067)
One year event rate in FRISC II



(Norhammar et al J Am Coll Card 2004; 43; 585)

Revascularization in acute coronary syndromes

Early PCI vs. thrombolysis in diabetic patients with AMI
Fibrinolysis (n = 99) or Primary PCI (n = 103)



(Hsu et al Heart 2002;88: 268)

Management of diabetes and glucose control before, during and after PCI and CABG

Diabetes and coronary revascularization

ESC POCKET GUIDELINES
Committee for Practice Guidelines
and patient care in Europe

Mechanical reperfusion by means of primary PCI is the revascularization mode of choice in a diabetic patient with acute MI.

I

A

GUIDELINES ON DIABETES, PRE-DIABETES
AND CARDIOVASCULAR DISEASES

For more information
www.escardio.org

Management of diabetes and glucose control before, during and after PCI and CABG

Diabetes and coronary revascularization

By pass surgery versus PCI


Adjunctive therapy

Revascularization in acute coronary syndromes

Glucose control

Revascularization in acute coronary syndromes

Mortality predictors in invasively managed patients with ACS



n = 1 222

Diabetes

No 1 067

Yes 155



(Norhammar et al J Am Coll Card 2004; 43; 585)

The importance of glucose control

Glycemia and mortality following PCI

(n=1 612)


Glucometabolic classification via fasting glucose



(Muhlestein et al. Am Heart J, 2003;146: 351)

The importance of glucose control

Target vessel revascularization and pre-procedural glycemia
Patients with diabetes (n=162); Follow up = 9 months




(Lindsay et al. Cardiovasc Revasc Med, 2007; 8:15)

The importance of glucose control

Glycemia and mortality after CABG


Effect of the institution of continuous insulin infusion



(Furnary et al. J Thorac Cardiovasc Surg, 2003;146:1007)

The importance of glucose control

Annualized mortality in all CABG with/without diabetes following a glucose control programme



(Furnary et al. J Thorac Cardiovasc Surg, 2003;146:1007)

Management of diabetes and glucose control before, during and after PCI and CABG

Diabetes and coronary revascularization

By pass surgery versus PCI

Adjunctive therapy

Revascularization in acute coronary syndromes

Glucose control

Unresolved issues

Unresolved issues

On the amount and quality of presently available information

- Limited
- Retrospective
- Therapy not updated
- Mostly subgroup-based
- Diabetes poorly described
- Glucose lowering therapy undefined

Unresolved issues

On urgently needed information

- **Trials dedicated to diabetic patients**
 - Accurately characterised patients
 - Well defined concomitant therapy
 - Carefully described glucose lowering drugs
- **Mode of revascularization**
 - single vs. multivessel disease
 - optimised technique
- **The impact of tight glycemetic control**

Unresolved issues

Important ongoing trials

FREEDOM

Diabetes mellitus type 2
Randomised to CABG or PCI (+DES)
Death, MI or repeat revascularization
Follow up 5 years

BARI IID

Diabetes mellitus type 2
Revascularization or optimal medical therapy
Glucose lowering randomised
Follow up 6 years

CARDia

Diabetes mellitus type 2
CABG or PCI – modern techniques

Management of cardiovascular disease

Diabetes and coronary revascularization

Recommendation	Class	Level
Treatment decisions regarding revascularization in patients with diabetes should favour coronary artery bypass surgery over percutaneous intervention.		
Glycoprotein IIb/IIIa inhibitors should not be used in a diabetic patient.	I	B
When PPCI is performed in a diabetic patient, drug-eluting stents (DES) should be used.	Ila	B
Mechanical reperfusion by means of primary PCI is the revascularization mode of choice in a diabetic patient with acute MI.	I	A

Time for questions!!